Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Income from Continuing Operations (2019 - 2025)

Historic Income from Continuing Operations for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$184.9 million.

  • BridgeBio Pharma's Income from Continuing Operations fell 1259.21% to -$184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$777.2 million, marking a year-over-year decrease of 7234.73%. This contributed to the annual value of -$543.3 million for FY2024, which is 1682.42% up from last year.
  • Per BridgeBio Pharma's latest filing, its Income from Continuing Operations stood at -$184.9 million for Q3 2025, which was down 1259.21% from -$183.8 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Income from Continuing Operations high stood at -$19.1 million for Q1 2024, and its period low was -$267.4 million during Q4 2024.
  • Its 5-year average for Income from Continuing Operations is -$153.4 million, with a median of -$162.2 million in 2023.
  • In the last 5 years, BridgeBio Pharma's Income from Continuing Operations surged by 8659.48% in 2024 and then tumbled by 64071.27% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Income from Continuing Operations (Quarter) stood at -$180.6 million in 2021, then grew by 19.62% to -$145.1 million in 2022, then tumbled by 32.37% to -$192.1 million in 2023, then crashed by 39.19% to -$267.4 million in 2024, then surged by 30.84% to -$184.9 million in 2025.
  • Its Income from Continuing Operations stands at -$184.9 million for Q3 2025, versus -$183.8 million for Q2 2025 and -$141.1 million for Q1 2025.